Denver Wealth Management Inc. Acquires New Shares in Merck & Co., Inc. (NYSE:MRK)

Denver Wealth Management Inc. acquired a new stake in Merck & Co., Inc. (NYSE:MRKFree Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 1,881 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds have also bought and sold shares of MRK. Ruedi Wealth Management Inc. boosted its holdings in Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the period. AlphaMark Advisors LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at $34,000. Valued Wealth Advisors LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $42,000. TFO Wealth Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 108.1% during the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after acquiring an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth $50,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MRK has been the subject of a number of research analyst reports. TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research note on Monday, March 11th. Finally, Barclays increased their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $129.71.

Get Our Latest Report on MRK

Merck & Co., Inc. Trading Down 0.5 %

Shares of Merck & Co., Inc. stock opened at $130.35 on Wednesday. The stock has a market capitalization of $330.13 billion, a PE ratio of 931.07, a P/E/G ratio of 0.52 and a beta of 0.38. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The company’s fifty day simple moving average is $125.45 and its 200-day simple moving average is $113.20. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. The firm had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insider Activity

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.